Clinical trials: Bleeding Diathesis
Essential Thrombocythemia
Anagre Cap. in Patients With High-Risk Essential Thrombocythemia
This study is to evaluate the efficacy and safety according to incremental dosing for 8 weeks and duration of administration for 1 year in patients with high-risk essential thrombocythemia.
- Trial name
- NCT03232177
- Testing
- Anagre Cap.
- Where
- 21 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Yuhan Corporation
Chronic Myeloproliferative Disorders, Leukemia
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00066417
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Autoimmune Thrombocytopenic Purpura
Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).
- Trial name
- NCT00107913
- Testing
- Doxil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hematology and Oncology Specialists
Immune Thrombocytopenia, Blood Platelet Disorder
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.
- Conditions
- Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic
- Trial name
- NCT06291415
- Testing
- HMPL-523
- Where
- 28 sites in United States, Australia and 3 more
- Sponsor
- Hutchmed
Von Willebrands Disease
Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)
The purpose of this study is to improve the investigators ability to diagnose von Willebrand Disease (VWD), a common inherited bleeding disorder.
- Trial name
- VWF-phV (NCT02466789)
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Jonathan Roberts
CALR Gene Mutation, Essential Thrombocythemia
CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia
This early phase I trial studies how well the use of a continuous positive airway pressure (CPAP) machine works in treating obstructive sleep apnea in patients with polycythemia vera or essential thrombocythemia.
- Conditions
- CALR Gene Mutation, Essential Thrombocythemia, JAK2 Gene Mutation, MPL Gene Mutation
- Trial name
- NCT03972943
- Testing
- Continuous Positive Airway Pressure, Patient Observation, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Utah
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects
Registry of Older Patients With Cancer
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
- Conditions
- Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma
- Trial name
- NCT01137825
- Where
- 7 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors
This Phase I/II clinical study will evaluate the safety and efficacy of valoctocogene roxaparvovec in patients with severe haemophilia A and inhibitors to FVIII.
- Trial name
- GENEr8-INH (NCT04684940)
- Testing
- Valoctocogene roxaparvovec
- Where
- 9 sites in United States, Brazil and 5 more
- Volunteers
- 10 people
- Sponsor
- BioMarin Pharmaceutical
TTP - Thrombotic Thrombocytopenic Purpura
Construction of a Database for TTP
Information about patients was collected by reviewing the Hitech case system and telephone and outpatient follow-up, and the case database was constructed by Epidata software.
- Trial name
- NCT05571774
- Testing
- collection data
- Where
- China
- Volunteers
- 500 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Primary Immune Thrombocytopenia
Observational Study on the Outcome of Patients With ITP Who Underwent Splenectomy After 2010
Retrospective data collection on ITP patients who underwent splenectomy from 01/01/2010 to 12/31/2022. The expected enrollment period is 6 months. The observation period of the enrolled patients is at least 1 year.
- Trial name
- NCT06466824
- Volunteers
- 157 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Mild Hemophilia
Ultrasound Assessment of Joint Health in Patients With Mild Hemophilia (Factor Levels 5-40%)
Currently, few recommendations exist for patients with mild hemophilia, who represent approximately 60% of the hemophilia population.
- Trial name
- echoSAHM (NCT07719647)
- Testing
- Joint Ultrasound (HEAD-US), Blood Sample for Coagulation Factor Measurement
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hemophilia A, Hemophilia B
Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)
Haemophilia A and haemophilia B are inherited bleeding disorders resulting from the absence or deficiency of coagulation factors VIII and IX, respectively.
- Trial name
- CHALE (NCT06158334)
- Testing
- Describe the respective haemostatic efficacy of Elocta® for haemopilia A during surgical procedures, Describe the respective haemostatic efficacy of Alprolix® for haemopilia B during surgical procedures
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Hospices Civils de Lyon
Hemophilia A
Prophylaxis Versus On-demand Therapy Through Economic Report
The project is a controlled observational, multicenter, prospective data collection on secondary prophylaxis with Kogenate Bayer in adolescents and adults with severe haemophilia A (FVIII < 1%).
- Trial name
- POTTER (NCT01159587)
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Bayer
Acquired Bleeding Disorder, Cirrhosis
Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign…
- Trial name
- NCT01562821
- Testing
- activated recombinant human factor VII
- Where
- 7 sites in China, Taiwan and 1 more
- Volunteers
- 235 people
- Sponsor
- Novo Nordisk A/S
Von Willebrand Disease (VWD), Type 2
Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease
This randomized clinical trial with a cross-over design is being conducted at the Department of Clinical Pharmacology at the Medical University of Vienna, and a total of 4-6 patients with type 2B von Willebrand disease (VWD) will…
- Trial name
- BT200-VWD2B (NCT07273721)
- Testing
- BT200
- Where
- Austria
- Volunteers
- 6 people
- Sponsor
- Medical University of Vienna
Hemophilia A, Hemophilia B
Study Evaluating Approach to Treatment of Haemophilia A and B in Spain
Analyze the clinical and therapeutic approach to treatment of haemophilia A and B in habitual clinical practice conditions in Spain.
- Trial name
- NCT00581438
- Volunteers
- 52 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin
Von Willebrand Disease
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
To evaluate the effect of ARC1779, a therapeutic oligonucleotide ("aptamer") in patients with Type2B von Willebrand Disease.
- Trial name
- NCT00694785
- Testing
- ARC1779
- Volunteers
- 2 people
- Sponsor
- Archemix Corp.
Acquired Bleeding Disorder, Bleeding During/Following Surgery
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
This trial is conducted in Asia, Europe and Oceania. The aim of this trial is to evaluate the efficacy of placebo and activated recombinant human factor VII in patients having undergone allogeneic or autologous stem cell…
- Trial name
- NCT01562158
- Testing
- standard therapy, activated recombinant human factor VII
- Where
- 46 sites in United States, Australia and 14 more
- Volunteers
- 100 people
- Sponsor
- Novo Nordisk A/S
Hemophilia, AIDS
Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)
Background: Over 80% of the hemophiliac population who became infected with HIV prior to 1985 are also co-infected with HCV. Thus, hemophiliacs represent an important population for studies of the natural history of these chronic…
- Trial name
- NCT00340548
- Where
- 15 sites in United States
- Volunteers
- 333 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.